Please use this identifier to cite or link to this item: http://hdl.handle.net/10316/90781
Title: Tailoring drug and gene codelivery nanosystems for glioblastoma treatment
Authors: Silva, Jessica
Basso, João
Mendes, Maria
Sousa, João
Pais, Alberto 
Vitorino, Carla
Keywords: Co-delivery; Drug delivery; Gene therapy; Glioblastoma; miRNA delivery; Nanoparticle; Nanotherapy
Issue Date: 2020
Publisher: Elsevier
Project: PEst- OE/QUI/UI0313/2014 
PEst- UID/NEU/04539/2013 
POCI-01-0145-FEDER- 016648 
POCI-01-0145-FEDER-007440 
POCI-01-0145-FEDER-007630 
SFRH/BD/133996/2017 
Serial title, monograph or event: Advances and Avenues in the Development of Novel Carriers for Bioactives and Biological Agents
Abstract: Glioblastoma is the most common primary and aggressive brain tumour, with an increasing incidence worldwide. The prognosis of this disease is still poor, with a median survival time not exceeding two years. Standard-of-care therapy includes surgical resection, radio- and chemotherapy, but nearly all patients experience progression of the disease. This may be ascribed to the heterogeneity, invasiveness and resistance of tumour cells, along with the struggle that many chemical drugs present in effectively crossing the dual blood brain-blood brain tumour barrier. Considering the hurdles associated to traditional therapeutic approaches, there is a pressing need to improve patient care, as treatments currently available have little effect on the overall survival. Therefore, the use of adjuvant chemotherapeutics in combination with temozolomide, a first-line drug, and novel molecularly-targeted approaches against both tumor and stem cells and respective microenvironment are under investigation. This chapter addresses the development of innovative multi-target nanomedicines, comprising complementary chemo- (e.g. temozolomide) and gene therapeutic (antimiR and miRNA mimic) agents, combined with targeting ligands within a single nanostructure directed at the treatment of glioblastoma multiforme. The approach aims at providing significantly improved therapeutics, as treatments currently available have little effect on overall survival.
URI: http://hdl.handle.net/10316/90781
ISBN: 9780128196663
DOI: 10.1016/B978-0-12-819666-3.00005-5
Rights: embargoedAccess
Appears in Collections:I&D CQC - Livros e capítulos de livros

Files in This Item:
File Description SizeFormat Login
Chapter 5.pdf695.84 kBAdobe PDFEmbargo Access    Request a copy
Show full item record

Page view(s)

42
checked on Sep 24, 2020

Download(s)

1
checked on Sep 24, 2020

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.